Template talk:COVID-19 vaccine candidates
Latest comment: 2 years ago by Ybsone in topic Add AZD2816
![]() | This template does not require a rating on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Purpose
editShawnqual - 1) why is working from a template an improvement? It interferes with ease of editing, imo; 2) the COVID-19 pandemic portal and links are already at the bottom of the article. You had them below the table in mid-article, a duplication and out of place. Zefr (talk) 05:29, 25 May 2020 (UTC)
- Zefr - 1) It is easier to manage and edit the data here imo, as it de-clutters the source code of the article. 2) Made an error with the Portal link, it has since been removed, thanks to MiasmaEternal.•Shawnqual• 📚 • 💭 05:39, 25 May 2020 (UTC)
- Shawnqual - I'm not 100% objecting to using the template, but thought perhaps your motives were a) to have a [COVID-19 vaccine - Clinical trials started in 2020] template link in several other COVID-19 articles (not sure this is requested or needed), b) the table occupied excessive space or code, and interfered with smooth use on various devices, like tablets or phones, and would be better used in the hidden format, or c) the table is likely to enlarge soon with candidates and references as more clinical trial results are released, and more candidates go into Phase I studies. Having said that, it's arguable that most users visiting the article would prefer just the table for quickly screening progress, i.e., it may well be the most useful piece of the article. Perhaps this should be taken to the article talk page to get community input on what's preferred among the 100+ editors who watch and contribute to the article. Zefr (talk) 13:32, 25 May 2020 (UTC)
Add AZD2816
editFirst COVID-19 variant vaccine candidate AZD2816 by AstraZeneca. Current AZ vaccine is Vaxzevria, formally AZD1222. "AZD2816 has been built using the same adenoviral vector platform as with Vaxzevria, with minor genetic alterations to the spike protein based on the Beta (B.1.351, South African) variant." [1] [2] "AZD2816 is a vaccine candidate currently undergoing Phase II/III trials". YBSOne (talk) 10:30, 8 October 2021 (UTC)